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Passive Antibody Therapy: Potentially the First 
COVID-19 Treatment 
Caterina Erdas 
While the world anxiously waits for a 
COVID-19 vaccine, thousands of people are in critical 
condition, in need of help today. Scientists are wonder- 
ing what tools they have now to prevent the spread of 
COVID-19 and help save the lives of patients in critical 
condition. Passive antibody therapy may be the solu- 
tion. 
An antibody is a small molecule created by the 
immune system to help fight an infection. Humans 
only obtain an effective antibody for an infection after 
they have become infected. Once the body is initially 
infected, a chain of immune system processes is set off, 
including the development of a specialized antibody. 
Through the process of trial and error, the body devel- 
ops an antibody, creates millions of copies, and dis- 
perses them throughout the body in the blood stream. 
An antibody has a specialized region that binds to the 
protein coating of a virus or the outer membrane of an 
invasive cell.1 
There are many types of antibodies that work 
in different ways to neutralize an infection. Some work 
by completely surrounding the infectious agent and 
preventing it from replicating. Other antibodies bind 
to the infectious agent and tag it for other cells in the 
immune system to kill it.1 Once the infection is cleared, 
the immune system will keep creating that antibody 
for a short period of time, or for the rest of the human’s 
life. No matter the strategy, antibodies are a powerful 
and effective biological adaptation to fight an infection. 
The idea behind passive antibody treatment 
is: Why re-invent the wheel? Humans who have just re- 
covered from an infection, in our case COVID-19, will 
have high levels of the effective, specialized antibody 
in their blood. Theoretically, if you take the convales- 
cent plasma (filtered blood that doesn’t have any blood 
cells but does have the antibodies for the pathogen of 
interest) from the recovered patient and inject it into 
a sick or susceptible patient, they will have the anti- 
bodies to fight off the infection. The immune system 
created a great treatment, so instead of synthesizing 
anew treatment, which takes a lot of time, doctors can 
give a plasma transplant from a recovered patient to a 
critical patient and potentially save their life. 
Doctors and scientists have been trying pas- 
sive antibody treatment for coronaviruses in general 
and with COVID-19. In SARS1 and MERS, studies 
showed that convalescent plasma administered early 
on in the infection improved the health of patients. 
In China, convalescent plasma was administrated to 
10 COVID-19 patients, and all 10 patients showed 
improvement after 1-3 days of treatment. There are 
other similar studies that show promising results but 
have small sample sizes and study design limitations. 
While the extent of the effectiveness of passive anti- 
body treatment cannot currently be determined, the 
data available suggests that antibody treatment is not 
harmful and could improve the symptoms of patients 
permanently.2 
The first step to start treating many COVID-19 
patients with passive antibody testing is scientific vali- 
dation. Safety is the first question that scientists need 
to answer in a rigorous clinical study, followed by 
evaluating passive antibody testing effectiveness in 
mildly ill to critically ill adult patients, and finally 
children. After the extent of the treatment is 
characterized, a structural framework needs to be 
built to collect and distribute convalescent plasma. 
Recovered people from COVID-19 are not hard to 
find, but blood donation 
10
centers are facing severe blood short- ages because 
they have had to close their hospital locations.2 
Scientific investigation and a solution 
to collect large quantities of convalescent plasma is 
needed before passive antibody testing can be widely 
administered. In conclusion, passive antibody treat- 
ment has the potential to save the lives of patients and 
prevent the spread of COVID-19 before a vaccine is 
created and distributed. If you contract COVID-19 and 
fully recover, look into convalescent plasma donation. 
Your donation could be invaluable in saving a patient 
with COVID-19 or fueling research for a long-term 
COVID-19 passive antibody treatment. 
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